Kenneth L Duchin

Ken Duchin is Chief Scientific Officer/Vice President of Trial Professionals Consultant Group. He earned his BA in chemistry at Drew University and received his PhD degree in pharmacology from the College of Medicine and Dentistry of New Jersey. He completed his post-doctoral training in renal physiology at University of Colorado. He joined ER Squibb and Sons and became Executive Director, Human Pharmacology and was responsible for various clinical pharmacology programs in several therapeutic areas and served as Team Leader for fosinopril. He then joined IVAX Corporation and was involved in the development of complex generic products and novel oncology and urological products. After eight years, he moved to Noven Pharmaceuticals where he led the clinical development of Daytrana (transdermal methylphenidate). He also worked for Theravance in South San Francisco as Head of Clinical Pharmacology.

In addition, he managed preclinical and clinical programs at TheraVida, a company with a product for overactive bladder and ProtaMed a company that focused on amyloid diseases. Ken also spent three years at Asubio Pharmaceuticals as Executive Director, Clinical Pharmacology and Global Project Leader. Since 2015, he has been an independent consultant assisting companies with their pre-clinical, clinical pharmacology and clinical research needs, medical writing, scientific due diligence, and business development. Ken has held teaching positions at Barry University and Medical College of Pennsylvania and served on the editorial board for the Journal of Clinical Pharmacology. His publications include over forty-five peer reviewed articles, several book chapters and co-inventor on nine patents.